Beyond the Adenoma Valley: From FIPA to Gigantism and Back. Chair Interview
Aart J. van der Lely (The Netherlands)
Geoffrey Harris Prize Lecture
Symposium 3: Senescence and plasticity in the anterior pituitary
Pituitary stem cells: quest for hidden functions
Hugo Vankelecom (Belgium)
The pituitary is the ‘master’ endocrine gland, governing the fundamental processes of body growth, metabolism, reproduction and stress. The past decade, it progressively became clear that the pituitary, like many adult tissues, harbors a population of stem cells. While the molecular portrayal of these cells is continually expanding, their function remains essentially hidden. From recent […]
Programmed cell senescence: IL-6 role in the pituitary
Eduardo Arzt (Argentina)
Cellular senescence is a state of permanent and stable proliferative arrest in G1 phase of the cell cycle through activation of the p53/p21 and pRb/p16 signalling pathways. Oncogene-induced senescence (OIS) is a highly proliferative state, which mimics transformation, but this mitotic burst is gradually replaced by senescence. Several lines of evidence have implicated OIS as a […]
Symposium 7: The chronic syndromes of patients with cured pituitary diseases
Acromegaly: 10 years after cure
Johannes Romijn (The Netherlands)
Appropriate treatment of acromegaly results in biochemical control or cure and reduces signs and symptoms, morbidity and excess mortality. Nonetheless, many of these patients still have considerable decreases in quality of life parameters and suffer from increased morbidity due to combinations of factors, including pituitary insufficiency despite optimal endocrine substitution, irreversible effects of previous GH/IGF-1 […]
Cushing's disease: 10 years after cure
Elena Valassi (Spain)
Recent evidence suggests that resolution of hypercortisolism in Cushing’s disease (CD) may not lead to complete remission of the clinical abnormalities associated with this condition. In particular, elevated cardiovascular risk may persist in ‘cured’ CD patients long-term after eucortisolism has been achieved. This is believed to be related with the maintenance of visceral obesity and […]
Craniopharyngeoma: 10 years after cure
Hermann Müller (Germany)
Childhood-onset craniopharyngiomas are rare intracranial embryonal malformations of the sellar region arising from remnants of Rathke’s pouch that require life-long control and management of the endocrine, ophthalmological and neuropsychological deficits caused by the tumors and their treatment. Craniopharyngiomas show low-grade histological malignancy and frequently affect hypothalamic/pituitary regions and the optic chiasm due to their location. […]
Symposium 13: Management of Cushing's syndrome
New developments in the medical treatment of Cushing's syndrome
Richard Feelders (The Netherlands)
Cushing’s disease (CD), caused by a corticotroph pituitary adenoma, is associated with multi-system morbidity and when untreated or suboptimally treated with an increased mortality. Transsphenoidal adenomectomy is the first choice of treatment for CD. Medical treatment is an option in patients in whom surgery is not successful or not feasible. Medical therapy for CD can […]
Rethinking Familial Adrenal Cushing's
Maya Lodish (USA)
Primary adrenal Cushing syndrome is the result of cortisol hypersecretion mainly by adenomas and, rarely, by bilateral micronodular or macronodular adrenocortical hyperplasia. cAMP-dependent protein kinase A (PKA) signaling is the major activator of cortisol secretion in the adrenal cortex. Many adenomas and hyperplasias associated with primary hypercortisolism carry somatic or germline mutations of genes that […]
Symposium 15: In the rhythm of EYES: Let's dance!
Debate 4: Should we treat subclinical Cushing’s syndrome?
Against: Should we treat subclinical Cushing’s syndrome?
Paul Stewart (UK)
The term subclinical Cushing syndrome arose at the turn of the millennium with the description of large Italian study of adrenal incidentalomas. Of 1096 patients from 26 centres, 9.2% had ‘subclinical Cushing’s’ (JCEM, 2000; 85:637-644). Since then over 300 publications have detailed this newly discovered endocrine diagnosis, and herein lies the main issue. The definition […]
Audience Reflection: Should we treat subclinical Cushing’s syndrome?
Jens Otto Lunde Joregensen (Denmark)
For: Should we treat subclinical Cushing’s syndrome?
Massimo Terzolo (Italy)
Sub-clinical Cushing’s syndrome is an ill-defined condition whose most frequent clinical scenario is characterized by 3 major features: 1) presence of an adrenal incidentaloma, 2) in a patient who does not present classic Cushingoid signs, 3) with a work-up of the HPA axis suggesting adrenal autonomy and low grade cortisol excess. Although a classic Cushing […]
Symposium 24: Endocrine neoplasias: new associations
ECE pre-congress Nurse Course